Cis-Asarone

Cis-Asarone

SCHEMBL29655982

C/C=C\c1cc(OC)c(OC)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 1.00
CYP3A4 P08684 1/20 1.00
NFE2L2 Q16236 2/20 0.59
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
TSHR P16473 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
CYP1A1 P04798 5/20 0.57
CYP1B1 Q16678 5/20 0.57
CYP1A2 P05177 4/20 0.57
ABCG2 Q9UNQ0 1/20 0.52
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NOD2 Q9HC29 2/20 0.43
TYR P14679 1/20 0.42
PRKDC P78527 1/20 0.42
SNCA P37840 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
APP P05067 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trans-Asarone SCHEMBL528746 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Cis-Asarone SCHEMBL528747 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL940800 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL29433647 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL29268894 0.98 HMGCR (0.95) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL30487992 0.88 CYP3A4 (0.78) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL13498711 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL13324430 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL12621133 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL3486261 0.83 HMGCR (0.70) HMGCRCYP3A4NFE2L2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111778165-B Aspergillus niger DFY1 and application thereof 哈尔滨工业大学 2022-10-25 CN claimed
US-12543733-B2 Biofumigant composition and a process for the preparation thereof INSTITUTE OF BIORESOURCES AND SUSTAINABLE DEVELOPMENT (IN) 2026-02-10 US disclosed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
US-20240389586-A1 BIOFUMIGANT COMPOSITION AND A PROCESS FOR THE PREPARATION THEREOF INSTITUTE OF BIORESOURCES AND SUSTAINABLE DEVELOPMENT (IN) 2024-11-28 US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240108676-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-04-04 US disclosed
US-11883454-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2024-01-30 US disclosed
US-20230405067-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2023-12-21 US disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 US disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 US disclosed
CN-111778165-B Aspergillus niger DFY1 and application thereof 哈尔滨工业大学 2022-10-25 CN disclosed
WO-2022101932-A1 A NOVEL BIOFUMIGANT COMPOSITION AND A PROCESS FOR THE PREPARATION THEREOF INSTITUTE OF BIORESOURCES AND SUSTAINABLE DEVELOPMENT (IN) 2022-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 HMGCR 857/4885CYP3A4 2613/4885NFE2L2 4098/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 HMGCR 38/4885CYP3A4 1136/4885NFE2L2 3669/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 HMGCR 406/4885CYP3A4 1979/4885NFE2L2 2023/4885
US-12543733-B2 Biofumigant composition and a process for the preparation thereof ERG28, VIP, SI HMGCR 84/4885CYP3A4 901/4885NFE2L2 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.